CBGA (Cannabigerolic Acid): The Precursor Cannabinoid
CBGA is the acid precursor the cannabis plant uses to build THCA, CBDA and CBCA. See what it is, what mouse studies show, and why human evidence is missing.
Content last updated . This page has not been medically reviewed.
Overview and classification
CBGA (cannabigerolic acid) is a cannabinoid acid made by the cannabis plant. It is the shared precursor from which the plant builds other cannabinoid acids. [1] Because of that role it is sometimes called the "mother of all cannabinoids." [2] Reviewers describe it as a key compound in cannabinoid biosynthesis and the precursor to various phytocannabinoids. [3]Evidence labels used on this page: preclinical (cells/animals only), mixed, insufficient evidence, marketing claim.
Where it comes from
Three enzymes (CBCA synthase, CBDA synthase and THCA synthase) each convert CBGA into a different product: CBCA, CBDA and THCA. [1] These are the acid precursors of CBC, CBD and THC. [4] CBG forms when CBGA loses a carbon-dioxide group (decarboxylation). [3]The practical meaning: the cannabinoids in a finished plant or product reflect what happened to CBGA along the way. A product can hold a mix, and a single name or label does not reveal that mix. See cannabinoid and terpene chemistry and CBG.
What research shows
| Question | Label | What the sources say |
|---|---|---|
| Seizures | preclinical (cells/animals only); mixed | In mouse models, CBGA was the most potent of the compounds screened and boosted the anticonvulsant effect of the medicine clobazam. [5] However, it was proconvulsant (seizure-promoting) in another test, and a high dose increased spontaneous seizure frequency in mice. [5] The authors say several liabilities would need to be overcome. [5] |
| Any condition in people | insufficient evidence | A 2026 review of acidic cannabinoids reports a dearth of controlled human trials, plus chemical instability and low bioavailability. [4] |
Proper evidence not found for benefit or safety in people. We checked PubMed abstracts on CBGA pharmacology and pharmacokinetics. A pharmacokinetics review of non-intoxicating cannabinoids says research on CBGA and the other acids is thin and that the biggest gap is clinical investigation. [6] The mouse seizure result is also a warning: an effect that helps in one test can worsen things in another.
Marketing claims
Descriptions of CBGA as a special or "raw" ingredient in products are marketing claims. No human study read for this page supports a health claim, and the amount of CBGA in any one product or batch is not a universal figure. Check verified batch data; see product quality and certificates of analysis.Regulatory category (United States, read 2026-10-22)
The FDA quotes the 2018 Farm Bill definition of hemp as the plant and all derivatives, extracts, cannabinoids, isomers and acids, with a delta-9 THC concentration of not more than 0.3 percent on a dry weight basis. [7] That definition is being amended to total THC, with portions delayed to December 11, 2026. [8] A rule specific to CBGA was not verified, and other countries were not checked. Laws change, and this is not legal advice. See cannabis and CBD laws by country.Safety
Human safety data was not found in the sources read, so no safety claim is made. Anyone who is pregnant, breastfeeding, has epilepsy or another seizure disorder, or takes regular medicines should speak with a clinician before using any cannabinoid product. Keep products away from children; in the US, call Poison Help at 1-800-222-1222 or 911 in an emergency.Frequently asked questions
What is CBGA?
It is the cannabinoid acid the plant uses as the starting point for other cannabinoid acids. [1]
Why is CBGA called the mother cannabinoid?
Because other cannabinoid acids are made from it. [2] [1]
Does CBGA help with seizures?
Only mouse studies exist, and the results were mixed: some tests showed anticonvulsant effects, others showed seizure-promoting effects. [5]
Is CBGA the same as CBG?
No. CBG forms from CBGA by decarboxylation. [3]
References
- Domenech et al. X-ray crystal structures of the cannabinoid synthases CBCAS, CBDAS and THCAS. Current Research in Structural Biology. 2026. PubMed abstract read 2026-10-22.
- Russo et al. Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms. Cannabis and Cannabinoid Research. 2022. PubMed abstract read 2026-10-22.
- Jastrz�
- Singh et al. Therapeutic potential of acidic cannabinoids: an update. Journal of Cannabis Research. 2026. PubMed abstract read 2026-10-22.
- Anderson et al. Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy. British Journal of Pharmacology. 2021. PubMed abstract read 2026-10-22.
- Lacerda et al. Pharmacokinetics of Non-Psychotropic Phytocannabinoids. Pharmaceutics. 2025. PubMed abstract read 2026-10-22.
- US Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD): Questions and Answers. Read 2026-10-22.
- Congressional Research Service. Changes to the Statutory Definition of Hemp and Implications for Agricultural Policy (CRS In Focus IF13136), updated September 28, 2026. Read 2026-10-22.